Bard1 Life Sciences (BD1) Short Interest
Bard1 Life Sciences (ASX:BD1) had 0.05% of shares reported as short positions as of 29 Nov 2021, representing 50,000 shares. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Bard1 Life Sciences
Proteomics International is a pioneering medical technology company based in Perth, Western Australia, specializing in predictive diagnostics and bio-analytical services. The company operates at the forefront of proteomics, which involves the industrial-scale study of proteins. It focuses on developing and commercializing diagnostic tests, leveraging its expertise in this advanced field.
Short position
Bard1 Life Sciences (ASX:BD1) has 0.05% of its shares on issue reported as short positions as of 29 Nov 2021, or about 50,000 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has risen 0.05 percentage points. Its highest recorded short interest was 0.13% in August 2019. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 35, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4BD1 intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Bard1 Life Sciences
About
website
Be the first to discuss BD1
Start a research thread or post the first pulse update